{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:04:42Z","timestamp":1790327082447,"version":"4.1.0"},"publisher-location":"Cham","reference-count":161,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319965222","type":"print"},{"value":"9783319965239","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/164_2017_79","type":"book-chapter","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T06:12:59Z","timestamp":1514873579000},"page":"579-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in Pharmacotherapy Development: Human Clinical Studies"],"prefix":"10.1007","author":[{"given":"Raye Z.","family":"Litten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fertig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"79_CR1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","volume":"4","author":"B Abou-Khalil","year":"2008","unstructured":"Abou-Khalil B (2008) Levetiracetam in the treatment of epilepsy. Neuropsychiat Dis Treat 4:507\u2013523","journal-title":"Neuropsychiat Dis Treat"},{"key":"79_CR2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","volume":"37","author":"G Addolorato","year":"2002","unstructured":"Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37:504\u2013508","journal-title":"Alcohol Alcohol"},{"key":"79_CR3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D\u2019Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915\u20131922","journal-title":"Lancet"},{"key":"79_CR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","volume":"40","author":"O Ameisen","year":"2005","unstructured":"Ameisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40:147\u2013150","journal-title":"Alcohol Alcohol"},{"key":"79_CR5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/acer.13279","volume":"41","author":"RM Anthenelli","year":"2017","unstructured":"Anthenelli RM, Heffner JL, Wong E, Tibbs J, Russell K, Isgro M, Dinh E, Wehrle C, Worley MJ, Doran N (2017) A randomized trial evaluating whether topiramate aids smoking cessation and prevents alcohol relapse in recovering alcohol-dependent men. Alcohol Clin Exp Res 41:197\u2013206","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"79_CR6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","volume":"24","author":"RF Anton","year":"2004","unstructured":"Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24(4):421\u2013428","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","volume":"28","author":"RF Anton","year":"2008","unstructured":"Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28:5\u201312","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","volume":"29","author":"RF Anton","year":"2009","unstructured":"Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM, Stewart SH, Waid R, Malcolm R (2009) Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol 29:334\u2013342","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","volume":"168","author":"RF Anton","year":"2011","unstructured":"Anton RF, Myrick H, Wright TM, Latham PK, Am B, Waid LR, Randall PK (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 168:709\u2013717","journal-title":"Am J Psychiatry"},{"issue":"7","key":"79_CR10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/acer.13417","volume":"41","author":"RF Anton","year":"2017","unstructured":"Anton RF, Schacht JP, Voronin KE, Randall PK (2017) Aripiprazole suppression of drinking in a clinical laboratory paradigm: influence of impulsivity and self-control. Alcohol Clin Exp Res 41(7):1370\u20131380","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e3181db38bb","volume":"30","author":"A Arias","year":"2010","unstructured":"Arias A, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 30:318\u2013322","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-4-5","volume":"4","author":"D Arnone","year":"2005","unstructured":"Arnone D (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4:5","journal-title":"Ann Gen Psychiatry"},{"issue":"19\u201320","key":"79_CR13","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00213-016-4385-8","volume":"233","author":"AMA Aziz","year":"2016","unstructured":"Aziz AMA, Brothers S, Sartor G, Holm L, Heilig M, Wahlestedt C, Thorsell A (2016) The nociception\/orphanin FQ receptor agonist SR-8993 as a candidate therapeutic for alcohol use disorders: validation in rat models. Psychopharmacology (Berl) 233(19\u201320):3553\u20133563","journal-title":"Psychopharmacology (Berl)"},{"key":"79_CR14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archpsyc.1992.01820080007002","volume":"49","author":"TF Babor","year":"1992","unstructured":"Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B (1992) Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 49:599\u2013608","journal-title":"Arch Gen Psychiatry"},{"key":"79_CR15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","volume":"39","author":"A Bejczy de","year":"2015","unstructured":"de Bejczy A, Lof E, Walther L, Gutertstam J, Hammarbeg A, Ansanovska G, Franck J, Isaksson A, Soderpalm B (2015) Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol Clin Exp Res 39:2189\u20132199","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/adb.12106","volume":"20","author":"RL Bell","year":"2013","unstructured":"Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, Becker HC (2013) Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol 20:38\u201342","journal-title":"Addict Biol"},{"key":"79_CR17","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","volume":"26","author":"EM Beraha","year":"2016","unstructured":"Beraha EM, Salemink E, Goudriaan AE, Bakker A, de Jong D, Smits N, Zwart JW, van Geest D, Bodewits P, Schiphof T, Defourny H, van Tricht M, van den Brink W, Rw W (2016) Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicenter, randomized, double-blind controlled trial. Eur Neuorpsychopharmacol 26:1950\u20131959","journal-title":"Eur Neuorpsychopharmacol"},{"key":"79_CR18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW (2014) A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38:1481\u20131488","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"79_CR19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.12779","volume":"121","author":"D Boels","year":"2017","unstructured":"Boels D, Victorri-Vigneau C, Grall-Bronnec M, Toure A, Garnier A, Turcant A, Le Roux G (2017) Baclofen and alcohol-dependent patients: a real risk of severe self-poisoning. Basic Clin Pharmacol Toxicol 121(4):353\u2013359","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"79_CR20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W Brink van den","year":"2013","unstructured":"van den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K (2013) Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 48:570\u2013578","journal-title":"Alcohol Alcohol"},{"key":"79_CR21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","volume":"28","author":"W Brink van den","year":"2014","unstructured":"van den Brink W, Sorensen P, Torup L, Mann K, Gual A (2014) Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomized controlled study. J Psychopharmacol 28:733\u2013744","journal-title":"J Psychopharmacol"},{"issue":"8","key":"79_CR22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1530-0277.2008.00706.x","volume":"32","author":"KJ Brower","year":"2008","unstructured":"Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA (2008) A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 32(8):1429\u20131438","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR23","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/acer.12445","volume":"38","author":"ES Brown","year":"2014","unstructured":"Brown ES, Davila D, Nakamura A, Carmody TJ, Rush AJ, Lo A, Holmes T, Adinoff B, Caetano R, Swann AC, Sunderajan P, Bret ME (2014) A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res 38:2113\u20132118","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/alcalc\/agl091","volume":"42","author":"W Bucknam","year":"2007","unstructured":"Bucknam W (2007) Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 42:158\u2013160","journal-title":"Alcohol Alcohol"},{"key":"79_CR25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-003-1645-1","volume":"172","author":"R Ciccocioppo","year":"2004","unstructured":"Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, Massi M (2004) Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociception\/orphanin FZ in alcohol-preferring. Psychopharmacology 172:170\u2013178","journal-title":"Psychopharmacology"},{"key":"79_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/nyas.13066","volume":"1366","author":"DA Collier","year":"2016","unstructured":"Collier DA, Bj E, Malki K, Mokrab Y (2016) Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery. Ann N Y Acad Sci 1366:61\u201375","journal-title":"Ann N Y Acad Sci"},{"key":"79_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1527-3458.2007.00004.x","volume":"13","author":"T Smedt De","year":"2007","unstructured":"De Smedt T, Raedt R, Vonck K, Boon P (2007) Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev 13:43\u201356","journal-title":"CNS Drug Rev"},{"key":"79_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1940-0640-8-12","volume":"8","author":"AC Re Del","year":"2013","unstructured":"Del Re AC, Gordon AJ, Lembke A, Harris AHS (2013) Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract 8:12","journal-title":"Addict Sci Clin Pract"},{"key":"79_CR29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/1871527314666150529144329","volume":"14","author":"I Diamond","year":"2015","unstructured":"Diamond I, Yao L (2015) From ancient Chinese medicine to a novel approach to treat cocaine addiction. CNS Neurol Disord Drug Targets 14:716\u2013726","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"79_CR30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"DJ Drobes","year":"2004","unstructured":"Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362\u20131370","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2008.02.004","volume":"64","author":"D Economidou","year":"2008","unstructured":"Economidou D, Hansson AC, Weiss F, Terasmaa A, Sommer WH, Cippitelli A, Fedeli A, Martin-Fardon R, Massi M, Ciccocioppo R, Heilig M (2008) Dysregulation of nociception\/orphanin FZ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 64:211\u2013218","journal-title":"Biol Psychiatry"},{"key":"79_CR32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1530-0277.2010.01392.x","volume":"35","author":"D Economidou","year":"2011","unstructured":"Economidou D, Cippitelli A, Stopponi S, Braconi S, Clementi S, Ubaldi M, Martin-Fardon R, Weiss F, Massi M, Ciccocioppo R (2011) Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat. Alcohol Clin Exp Res 35:747\u2013755","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1369-1600.2010.00291.x","volume":"17","author":"S Edwards","year":"2011","unstructured":"Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF (2011) Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol 17:76\u201385","journal-title":"Addict Biol"},{"key":"79_CR34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1530-0277.2008.00805.x","volume":"33","author":"SM Evans","year":"2009","unstructured":"Evans SM, Bisaga A (2009) Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 33:19\u201330","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0000000000000133","volume":"9","author":"DE Falk","year":"2015","unstructured":"Falk DE, Castle IJP, Ryan M, Fertig J, Litten RZ (2015) Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med 9:296\u2013303","journal-title":"J Addict Med"},{"issue":"4","key":"79_CR36","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1038\/tp.2017.71","volume":"7","author":"M Farokhnia","year":"2017","unstructured":"Farokhnia M, Schwandt ML, Lee MR, Bollinger JW, Farinelli LA, Amodio JP, Sewell L, Lionetti TA, Spero DE, Leggio L (2017) Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry 7(4):e1108","journal-title":"Transl Psychiatry"},{"issue":"8","key":"79_CR37","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","volume":"6","author":"JB Fertig","year":"2012","unstructured":"Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, Tompkins DA, Stout R (2012) A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 6(8):1421\u20131430","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR38","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1517\/14656566.6.12.2091","volume":"6","author":"WW Fleischhacker","year":"2005","unstructured":"Fleischhacker WW (2005) Aripiprazole. Expert Opin Pharmacolther 6:2091\u20132101","journal-title":"Expert Opin Pharmacolther"},{"key":"79_CR39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1530-0277.2011.01628.x","volume":"36","author":"HC Fox","year":"2011","unstructured":"Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R (2011) Prozosin effects on stress-and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36:351\u2013360","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","volume":"215","author":"LM Fucito","year":"2011","unstructured":"Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O\u2019Malley SS (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 215:655\u2013663","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"79_CR41","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","volume":"68","author":"FA Furieri","year":"2007","unstructured":"Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(11):1691\u20131700","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"79_CR42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34(11):1849\u20131857","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/add.12557","volume":"109","author":"JC Garbutt","year":"2014","unstructured":"Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV (2014) Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 109:1274\u20131284","journal-title":"Addiction"},{"key":"79_CR44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5498\/wjp.v6.i1.66","volume":"6","author":"PJ Gebicke-Haerter","year":"2016","unstructured":"Gebicke-Haerter PJ (2016) Systems psychopharmacology: a network approach to developing novel therapies. World J Psychiatr 6:66\u201383","journal-title":"World J Psychiatr"},{"key":"79_CR45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.yebeh.2007.02.007","volume":"10","author":"B Gomer","year":"2007","unstructured":"Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, Steinhjoff BJ, Schulze-Bonhage A (2007) The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10:486\u2013494","journal-title":"Epilepsy Behav"},{"issue":"8","key":"79_CR46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS (2015) Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiat 72(8):757\u2013766","journal-title":"JAMA Psychiat"},{"key":"79_CR47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.pra.0000452561.98286.1e","volume":"20","author":"B Green","year":"2014","unstructured":"Green B (2014) Prazosin in the treatment of PTSD. J Psychiatr Pract 20:253\u2013259","journal-title":"J Psychiatr Pract"},{"issue":"11","key":"79_CR48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","volume":"23","author":"A Gual","year":"2013","unstructured":"Gual A, He Y, Torup L, van den Brink W, Mann K (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23(11):1432\u20131442","journal-title":"Eur Neuropsychopharmacol"},{"key":"79_CR49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","volume":"177","author":"CL Haass-Koffler","year":"2017","unstructured":"Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Eltinge SE, Wallace PM, Long VM, Jayaram-Lindstrom N, Swift RM, Kenna GA, Leggio L (2017) Higher pressure in associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend 177:23\u201328","journal-title":"Drug Alcohol Depend"},{"key":"79_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00952990.2011.600396","volume":"38","author":"SG Hofmann","year":"2012","unstructured":"Hofmann SG, Huweler R, MacKillop JM, Kantak K (2012) Effects of D-cycloserine on craving to alcohol cues in problem drinkers: preliminary findings. Am J Drug Alcohol Abuse 38:101\u2013107","journal-title":"Am J Drug Alcohol Abuse"},{"key":"79_CR51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682\u2013690","journal-title":"Nat Chem Biol"},{"key":"79_CR52","first-page":"339","volume":"34","author":"TD Hurley","year":"2012","unstructured":"Hurley TD, Edenberg HJ (2012) Genes encoding enzymes involved in ethanol metabolism. Alcohol Res Curr Rev 34:339\u2013344","journal-title":"Alcohol Res Curr Rev"},{"key":"79_CR53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","volume":"75","author":"BA Johnson","year":"2008","unstructured":"Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34\u201356","journal-title":"Biochem Pharmacol"},{"key":"79_CR54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF02247375","volume":"112","author":"BA Johnson","year":"1993","unstructured":"Johnson BA, Campling GM, Griffiths P, Cowen PJ (1993) Attention of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study I healthy male volunteers. Psychopharmacology (Berl) 112:142\u2013144","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"79_CR55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","volume":"284","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284(8):963\u2013971","journal-title":"JAMA"},{"key":"79_CR56","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","volume":"361","author":"BA Johnson","year":"2003","unstructured":"Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677\u20131685","journal-title":"Lancet"},{"issue":"14","key":"79_CR57","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"198","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegund F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O\u2019Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 198(14):1641\u20131651","journal-title":"JAMA"},{"key":"79_CR58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","volume":"168","author":"BA Johnson","year":"2011","unstructured":"Johnson BA, Ait-Daoud N, Seneviratne C, Roach JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168:265\u2013275","journal-title":"Am J Psychiatry"},{"key":"79_CR59","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","volume":"170","author":"BA Johnson","year":"2013","unstructured":"Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud LMD (2013) Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT3 antagonist ondansetron. Am J Psychiatry 170:1020\u20131031","journal-title":"Am J Psychiatry"},{"key":"79_CR60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acer.12643","volume":"39","author":"JD Jones","year":"2015","unstructured":"Jones JD, Comer SD, Kranzler HR (2015) The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res 39:391\u2013402","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"79_CR61","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0b013e3180ca86e5","volume":"27","author":"KM Kampman","year":"2007","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O\u2019Brien CP (2007) A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 27(4):344\u2013351","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuron.2004.09.016","volume":"44","author":"AE Kelley","year":"2004","unstructured":"Kelley AE (2004) Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44:161\u2013179","journal-title":"Neuron"},{"key":"79_CR63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1530-0277.2008.00835.x","volume":"33","author":"GA Kenna","year":"2009","unstructured":"Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM (2009) A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 33:315\u2013323","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR64","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/acer.12410","volume":"38","author":"GA Kenna","year":"2014","unstructured":"Kenna GA, Zywiak WH, Swiftt RM, McGeary JE, Cliifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L (2014a) Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5\/-HTTLPR genotype: a laboratory study. Alcohol Clin Exp Res 38:1567\u20131574","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.alcohol.2014.04.005","volume":"48","author":"GA Kenna","year":"2014","unstructured":"Kenna GA, Zwiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L (2014b) Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. Alcohol 48:515\u2013522","journal-title":"Alcohol"},{"key":"79_CR66","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","volume":"21","author":"GA Kenna","year":"2015","unstructured":"Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L (2015) Role of the \u03b11 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol 21:904\u2013914","journal-title":"Addict Biol"},{"issue":"13","key":"79_CR67","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00213-015-3882-5","volume":"232","author":"F Kiefer","year":"2015","unstructured":"Kiefer F, Kirsch M, Bach P, Hoffmann S, Reinhard I, Jorde A, von der Goltz C, Spanagel R, Mann K, Loeber S, Vollstadt-Klein S (2015) Effects of D-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Psychopharmacology (Berl) 232(13):2353\u20132362","journal-title":"Psychopharmacology (Berl)"},{"key":"79_CR68","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/acer.13359","volume":"41","author":"CE King","year":"2017","unstructured":"King CE, Griffin WC, Luderman LN, Kates MM, McGinty JF, Becker HC (2017) Oxytocin reduces ethanol self-administration in mice. Alcohol Clin Exp Res 41:955\u2013964","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/00952991003674812","volume":"36","author":"CM Knapp","year":"2010","unstructured":"Knapp CM, Sarid-Segal O, Richardson MA, Sickles Colaneri L, Afshar M, Devine E, Streeter CC, Piechniczek-Buczek J, Ciraulo DA (2010) Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 36:102\u2013105","journal-title":"Am J Drug Alcohol Abuse"},{"key":"79_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000246","volume":"35","author":"CM Knapp","year":"2015","unstructured":"Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35:1\u20139","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR71","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/17425255.4.4.493","volume":"4","author":"S Kothare","year":"2008","unstructured":"Kothare S, Kaleyias J (2008) Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 4:493\u2013506","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"79_CR72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","volume":"27","author":"HR Kranzler","year":"2003","unstructured":"Kranzler HR, Piernucci-Lagha A, Feinn R, Hernandez-Avila C (2003) Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27:1150\u20131155","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1530-0277.2007.00608.x","volume":"32","author":"HR Kranzler","year":"2008","unstructured":"Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ, Oncken C (2008) Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 32:1\u20137","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM (2014) Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445\u2013452","journal-title":"Am J Psychiatry"},{"key":"79_CR75","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/13543784.16.7.935","volume":"16","author":"A Ledeboer","year":"2007","unstructured":"Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW (2007) Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 16:935\u2013950","journal-title":"Expert Opin Investig Drugs"},{"key":"79_CR76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40263-013-0137-z","volume":"28","author":"MR Lee","year":"2014","unstructured":"Lee MR, Leggio L (2014) Combined pharmacotherapies for the management of alcoholism rationale and evidence to date. CNS Drugs 28:107\u2013119","journal-title":"CNS Drugs"},{"key":"79_CR77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FBP.0000000000000258","volume":"27","author":"MR Lee","year":"2016","unstructured":"Lee MR, Weerts EM (2016) Oxytocin for the treatment of drug and alcohol use disorders. Behav Pharmacol 27:640\u2013648","journal-title":"Behav Pharmacol"},{"key":"79_CR78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0313-z","volume":"30","author":"MR Lee","year":"2016","unstructured":"Lee MR, Rohn MCH, Tanda G, Leggio L (2016) Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs 30:109\u2013123","journal-title":"CNS Drugs"},{"key":"79_CR79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/acer.12064","volume":"37","author":"L Leggio","year":"2013","unstructured":"Leggio L, Kenna GA (2013) Commentary: doxazosin for alcoholism. Alcohol Clin Exp Res 37:191\u2013193","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","volume":"9","author":"L Leggio","year":"2010","unstructured":"Leggio L, Garbutt JC, Addolorato G (2010) Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disor 9:33\u201344","journal-title":"CNS Neurol Disor"},{"key":"79_CR81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.pbb.2012.11.013","volume":"103","author":"L Leggio","year":"2013","unstructured":"Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, Addolorato G, Swift RM, Kenna GA (2013) A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav 103:784\u2013791","journal-title":"Pharmacol Biochem Behav"},{"key":"79_CR82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-014-3652-9","volume":"232","author":"L Leggio","year":"2015","unstructured":"Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna G (2015) A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology (Berl) 232:233\u2013243","journal-title":"Psychopharmacology (Berl)"},{"key":"79_CR83","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1111\/acer.13222","volume":"40","author":"RZ Litten","year":"2016","unstructured":"Litten RZ (2016) Nociceptin receptor as a target to treat alcohol use disorder: challenges in advancing medications development. Alcohol Clin Exp Res 40:2299\u20132304","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"79_CR84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","volume":"36","author":"RZ Litten","year":"2012","unstructured":"Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson BA, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NAD, Kampman K, Stout R (2012) Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 36(3):406\u2013416","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","volume":"7","author":"RZ Litten","year":"2013","unstructured":"Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R (2013) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7:277\u2013286","journal-title":"J Addict Med"},{"key":"79_CR86","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/acer.12669","volume":"39","author":"RZ Litten","year":"2015","unstructured":"Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF (2015) Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res 39:579\u2013584","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","volume":"37","author":"RZ Litten","year":"2016","unstructured":"Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB (2016a) Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subs Abuse 37:286\u2013298","journal-title":"Subs Abuse"},{"key":"79_CR88","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/acer.13093","volume":"40","author":"RZ Litten","year":"2016","unstructured":"Litten RZ, Falk DE, Ryan ML, Fertig JB (2016b) Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res 40:1368\u20131379","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"79_CR89","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1038\/tp.2015.41","volume":"5","author":"J MacKillop","year":"2015","unstructured":"MacKillop J, Few LR, Stojek MK, Murphy CM, Malutinok SF, Johnson FT, Hofmann SG, McGeary JE, Swift RM, Monti PM (2015) Transl Psychiatry 5(4):e544","journal-title":"Transl Psychiatry"},{"key":"79_CR90","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706\u2013713","journal-title":"Biol Psychiatry"},{"issue":"12","key":"79_CR91","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","volume":"26","author":"K Mann","year":"2016","unstructured":"Mann K, Torup L, Sorensen P, Gual A, Swift R, Walker B, van den Brink W (2016) Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuoropsychopharmacol 26(12):1941\u20131949","journal-title":"Eur Neuoropsychopharmacol"},{"key":"79_CR92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/00952990802308213","volume":"34","author":"JJ Mariani","year":"2008","unstructured":"Mariani JJ, Levin FR (2008) Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. Am J Drug Alcohol Abuse 34:683\u2013691","journal-title":"Am J Drug Alcohol Abuse"},{"key":"79_CR93","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hup.944","volume":"23","author":"G Martinotti","year":"2008","unstructured":"Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L (2008) Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Psychopharmacol Clin Exp 23:417\u2013424","journal-title":"Psychopharmacol Clin Exp"},{"key":"79_CR94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269881108089596","volume":"23","author":"G Martinotti","year":"2009","unstructured":"Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L (2009) Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs naltrexone. J Psychopharmacol 23:123\u2013129","journal-title":"J Psychopharmacol"},{"key":"79_CR95","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JCP.0000000000000228","volume":"34","author":"G Martinotti","year":"2014","unstructured":"Martinotti G, DiNicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, Aliotta F, Romanelli R, Verrastro V, Petruccelli F, Di Giannantonio M, Janiri L (2014) Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol 34:709\u2013715","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"79_CR96","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","volume":"56","author":"BJ Mason","year":"1999","unstructured":"Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56(8):719\u2013724","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"79_CR97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","volume":"14","author":"BJ Mason","year":"2009","unstructured":"Mason BJ, Light JM, Williams LD, Drobes DJ (2009) Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14(1):73\u201383","journal-title":"Addict Biol"},{"key":"79_CR98","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","volume":"174","author":"BJ Mason","year":"2014","unstructured":"Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174:70","journal-title":"JAMA Intern Med"},{"key":"79_CR99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2193-9616-1-17","volume":"1","author":"A Masoudi-Nejad","year":"2013","unstructured":"Masoudi-Nejad A, Mousavian Z, Bozorgmehr JH (2013) Drug-target and disease networks: polypharmacology in the post-genomic era. Silico Pharmacol 1:17","journal-title":"Silico Pharmacol"},{"key":"79_CR100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","volume":"66","author":"SA McKee","year":"2009","unstructured":"McKee SA, Harrison ELR, O\u2019Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 66:185\u2013195","journal-title":"Biol Psychiatry"},{"key":"79_CR101","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","volume":"70","author":"KB Mihalak","year":"2006","unstructured":"Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at \u03b14\u03b22 and a full agonist at \u03b17 neuronal nicotinic receptors. Mol Pharmacol 70:801\u2013805","journal-title":"Mol Pharmacol"},{"key":"79_CR102","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/npp.2016.234","volume":"42","author":"V Milivojevic","year":"2017","unstructured":"Milivojevic V, Sinha R (2017) Targeting stress pathophysiology to improve alcoholism relapse outcomes. Neuropsychopharmacology 42:987\u2013988","journal-title":"Neuropsychopharmacology"},{"key":"79_CR103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1530-0277.2007.00592.x","volume":"32","author":"R Miranda","year":"2008","unstructured":"Miranda R, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489\u2013497","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR104","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/adb.12192","volume":"21","author":"R Miranda","year":"2016","unstructured":"Miranda R, MacKillop J, Treloar H, Blanchard A, Tidey JW, Swift R, Chun T, Rohsenow DJ, Monti PM (2016) Biobehavioral mechanisms of topiramate\u2019s effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. Addict Biol 21:171\u2013182","journal-title":"Addict Biol"},{"key":"79_CR105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/JCP.0b013e318248ba69","volume":"32","author":"JM Mitchell","year":"2012","unstructured":"Mitchell JM, Grossman LE, Coker AR, Messing RO (2012a) The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol 32:269\u2013272","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR106","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","volume":"223","author":"JM Mitchell","year":"2012","unstructured":"Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012b) Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 223:299\u2013306","journal-title":"Psychopharmacology (Berl)"},{"key":"79_CR107","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000000213","volume":"10","author":"JM Mitchell","year":"2016","unstructured":"Mitchell JM, Arcuni PA, Weinstein D, Woolley JD (2016) Intranasal oxytocin selectively modulates social perception, craving, and approach behavior in subjects with alcohol use disorder. J Addict Med 10:182\u2013189","journal-title":"J Addict Med"},{"key":"79_CR108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pbb.2011.10.012","volume":"100","author":"N Moallem","year":"2012","unstructured":"Moallem N, Ray LA (2012) Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study. Pharmacol Biochem Behav 100:490\u2013493","journal-title":"Pharmacol Biochem Behav"},{"key":"79_CR109","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.jcp.0000138763.23482.2a","volume":"24","author":"EP Monnelly","year":"2004","unstructured":"Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I (2004) Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 24:532\u2013535","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","volume":"49","author":"KC Morley","year":"2014","unstructured":"Morley KC, Baillie A, Leung S, Addolorato G, Leggio L Haber PS (2014) Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 49:654\u2013660","journal-title":"Alcohol Alcohol"},{"key":"79_CR111","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1615\/CritRevBiomedEng.v38.i2.30","volume":"38","author":"JK Morrow","year":"2010","unstructured":"Morrow JK, Tian L, Zhang S (2010) Molecular networks in drug discovery. Crit Rev Biomed Eng 38:143\u2013156","journal-title":"Crit Rev Biomed Eng"},{"key":"79_CR112","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","volume":"25","author":"CA Muller","year":"2015","unstructured":"Muller CA, Geisel O, Petz P, Higl V, Kruger J, Stickel A, Beck A, Wernecke KD, Hellweg R, Heinz A (2015) High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Europ Neuropsychopharm 25:1167\u20131177","journal-title":"Europ Neuropsychopharm"},{"key":"79_CR113","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3181e75cff","volume":"30","author":"H Myrick","year":"2010","unstructured":"Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF (2010) The effect of aripiprazole in cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 30:365\u2013372","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR114","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1530-0277.2012.01958.x","volume":"37","author":"CA Pedersen","year":"2013","unstructured":"Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov-Polevoi A, Casey RL, Fender T, Garbutt JC (2013) Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 37:484\u2013489","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/adb.12362","volume":"22","author":"ST Peters","year":"2016","unstructured":"Peters ST, Bowen MT, Bohrer K, McGregor IS, Neumann ID (2016) Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens. Addict Biol 22:702\u2013711","journal-title":"Addict Biol"},{"key":"79_CR116","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acer.12926","volume":"40","author":"IL Petrakis","year":"2016","unstructured":"Petrakis IL, Desai N, Gueorguieva R, Arias A, O\u2019Brien E, Jane JS, Sevarino K, Southwick S, Ralevski E (2016) Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcohol Clin Exp Res 40:178\u2013186","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"79_CR117","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nmeth.3940","volume":"13","author":"L Pirhaji","year":"2016","unstructured":"Pirhaji L, Milani P, Leidl M, Curran T, Avila-Pacheco J, Clish CB, White FM, Saghatelian A, Fraenkel E (2016) Revealing disease-associated pathways by network integration of untargeted metabolomics. Nat Methods 13(9):770\u2013776","journal-title":"Nat Methods"},{"issue":"2","key":"79_CR118","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.drugalcdep.2013.06.019","volume":"133","author":"JG Plebani","year":"2013","unstructured":"Plebani JG, Lynch KG, Rennert L, Pettinati HM, O\u2019Brien CP, Kampman KM (2013) Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend 133(2):754\u2013758","journal-title":"Drug Alcohol Depend"},{"key":"79_CR119","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/npp.2015.348","volume":"41","author":"A Post","year":"2016","unstructured":"Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2016a) A selective nociception receptor antagonist to treat depression: evidence from preclinical and clinical studies. Neurophsychopharmaclogy 41:1803\u20131812","journal-title":"Neurophsychopharmaclogy"},{"key":"79_CR120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/acer.13147","volume":"40","author":"A Post","year":"2016","unstructured":"Post A, Smart T, Jackson K, Wilson J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O\u2019Malley S, Wong C (2016b) A proof-of-concept study to assess the nociception receptor antagonist LY2940094 as a new treatment for alcohol dependence. Alcohol Clin Exp Res 40:1935\u20131944","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR121","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15288\/jsa.1997.58.7","volume":"58","author":"Project MATCH Research Group","year":"1997","unstructured":"Project MATCH Research Group (1997) Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes. J Stud Alcohol 58:7\u201329","journal-title":"J Stud Alcohol"},{"issue":"10","key":"79_CR122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.biopsych.2016.03.2108","volume":"80","author":"MA Raskind","year":"2016","unstructured":"Raskind MA, Millard SP, Petie EC, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Hill J, Daniels C, Hendrickson R, Er P (2016) Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. Biol Psychiatry 80(10):736\u2013742","journal-title":"Biol Psychiatry"},{"key":"79_CR123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/a0015700","volume":"17","author":"LA Ray","year":"2009","unstructured":"Ray LA, Miranda R, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM (2009) A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 17:122\u2013129","journal-title":"Exp Clin Psychopharmacol"},{"key":"79_CR124","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1465-3362.2010.00185.x","volume":"29","author":"LA Ray","year":"2010","unstructured":"Ray LA, Heydari A, Zorick T (2010) Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev 29:568\u2013575","journal-title":"Drug Alcohol Rev"},{"key":"79_CR125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-011-2287-3","volume":"317","author":"LA Ray","year":"2011","unstructured":"Ray LA, Chin PF, Heyari A, Miotto K (2011) A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology (Berl) 317:341\u2013351","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"79_CR126","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/npp.2017.10","volume":"42","author":"LA Ray","year":"2017","unstructured":"Ray LA, Bujarski S, Shoptaw S, Roche DJO, Heinzerling K, Miotto K (2017) Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology 42(9):1776\u20131788","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"79_CR127","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","volume":"52","author":"M Reynaud","year":"2017","unstructured":"Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients \u2013 the ALPADIR study. Alcohol Alcohol 52(4):439\u2013446","journal-title":"Alcohol Alcohol"},{"key":"79_CR128","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1460-9568.2008.06455.x","volume":"28","author":"HN Richardson","year":"2008","unstructured":"Richardson HN, Lee SY, O\u2019Dell LE, Koob GF, Rivier CL (2008) Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. Eur J Neurosci 28:1641\u20131653","journal-title":"Eur J Neurosci"},{"issue":"4","key":"79_CR129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JCP.0b013e31825e213e","volume":"32","author":"C Richter","year":"2012","unstructured":"Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Forg A, Volkmar K, Glauner T, Schaefer M (2012) Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 32(4):558\u2013562","journal-title":"J Clin Psychopharmacol"},{"key":"79_CR130","doi-asserted-by":"publisher","unstructured":"Roberts W, Harrison ELR, McKee SA (2017a) Effects of varenicline on alcohol cue reactivity in heavy drinkers. Psychopharmacology. doi: https:\/\/doi.org\/10.1007\/s00213-017-4667-9 . [Epub ahead of print]","DOI":"10.1007\/s00213-017-4667-9"},{"key":"79_CR131","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0269881117699618","volume":"31","author":"W Roberts","year":"2017","unstructured":"Roberts W, Verplaetse TL, Moore K, Oberleitner L, Picciotto MR, McKee SA (2017b) Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms. J Psychopharmacol 31:906\u2013914","journal-title":"J Psychopharmacol"},{"issue":"10","key":"79_CR132","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1039\/C6MB00476H","volume":"12","author":"JL Robinson","year":"2016","unstructured":"Robinson JL, Nielsen J (2016) Integrative analysis of human omics data using biomolecular networks. Mol Biosyst 12(10):2953\u20132964","journal-title":"Mol Biosyst"},{"key":"79_CR133","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","volume":"25","author":"B Rolland","year":"2015","unstructured":"Rolland B, Labreuche J, Duhame A, Deheul S, Gautier S, Auffret M, Pignon B, Valin T, Bordet R, Cottencin O (2015) Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 25:1631\u20131636","journal-title":"Eur Neuropsychopharmacol"},{"key":"79_CR134","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/acer.13052","volume":"40","author":"LM Rorick-Kehn","year":"2016","unstructured":"Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz M, Lafuente C, Jimenez A, Benito A, Pedregal C, Weiss F, Statnick MA (2016) A novel, orally bioavailable nociception receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol seeking in animal models. Alcohol Clin Exp Res 40:945\u2013954","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/WNF.0b013e3181f0ed9a","volume":"33","author":"G Rubio","year":"2010","unstructured":"Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM, Jimenez-Arriero MA, Alamo C (2010) Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 33:250\u2013253","journal-title":"Clin Neuropharmacol"},{"key":"79_CR136","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/npp.2016.214","volume":"42","author":"ML Ryan","year":"2017","unstructured":"Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ (2017) A phase2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology 42:1012\u20131023","journal-title":"Neuropsychopharmacology"},{"key":"79_CR137","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00952990802082180","volume":"34","author":"O Sarid-Segal","year":"2008","unstructured":"Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickles L, Uwodukunda E, Richambault C, Koplow J, Ciraulo D (2008) The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse 34:441\u2013447","journal-title":"Am J Drug Alcohol Abuse"},{"key":"79_CR138","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/00952990903060150","volume":"35","author":"O Sarid-Segal","year":"2009","unstructured":"Sarid-Segal O, Cm K, Burch W, Richardson MA, Bahtia S, DeQuattro K, Afshar M, Richambault C, Sickels L, Devine E, Ciraulo D (2009) The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse 35:316\u2013319","journal-title":"Am J Drug Alcohol Abuse"},{"key":"79_CR139","first-page":"452","volume":"29","author":"SP Sattar","year":"2004","unstructured":"Sattar SP, Bhatia SC, Petty F (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29:452\u20134457","journal-title":"J Psychiatry Neurosci"},{"key":"79_CR140","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00213-014-3518-1","volume":"231","author":"JP Schacht","year":"2014","unstructured":"Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H (2014) Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl) 231:3799\u20133807","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"79_CR141","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1038\/npp.2014.144","volume":"39","author":"J Scholl","year":"2014","unstructured":"Scholl J, Gunthner J, Kollling N, Favaron E, Rushworth FS, Cj H, Reinecke A (2014) Arole beyond leaning for NMDA receptors in reward-based decision-making-a pharmacological study using d-cycloserine. Neuropsychopharmacology 39(12):2900\u20132909","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"79_CR142","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/npp.2015.84","volume":"40","author":"T Seif","year":"2015","unstructured":"Seif T, Simms JA, Lei K, Wegner S, Bonci A, Messing RO, Hopf FW (2015) D-serine and D-cycloserine reduce compulsive alcohol intake in rats. Neuropyschopharmacology 40(10):2357\u20132367","journal-title":"Neuropyschopharmacology"},{"issue":"4","key":"79_CR143","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1530-0277.1994.tb00054.x","volume":"18","author":"EM Sellers","year":"1994","unstructured":"Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18(4):879\u2013885","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR144","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"GJ Sills","year":"2006","unstructured":"Sills GJ (2006) The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6:108\u2013113","journal-title":"Curr Opin Pharmacol"},{"key":"79_CR145","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/npp.2011.268","volume":"37","author":"JA Simms","year":"2012","unstructured":"Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE (2012) Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology 37:906\u2013918","journal-title":"Neuropsychopharmacology"},{"key":"79_CR146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","volume":"33","author":"TL Simpson","year":"2009","unstructured":"Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin for alcohol dependence. Alcohol Clin Exp Res 33:255\u2013263","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR147","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","volume":"39","author":"TL Simpson","year":"2015","unstructured":"Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, Varon D, Raskind M, Saxon AJ (2015) A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 39:808\u2013817","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR148","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL (2016) Gabapentin misuse, abuse and diversion: a systematic review. Addiction 111:1160\u20131174","journal-title":"Addiction"},{"key":"79_CR149","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1530-0277.2010.01270.x","volume":"34","author":"M Stedman","year":"2010","unstructured":"Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S (2010) A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting, alcohol dependence. Alcohol Clin Exp Res 34:1822\u20131831","journal-title":"Alcohol Clin Exp Res"},{"issue":"2\u20133 Spec Issue","key":"79_CR150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FBP.0000000000000202","volume":"27","author":"Y Sun","year":"2016","unstructured":"Sun Y, Zhang Y, Wang F, Sun Y, Shi J, Lu L (2016) From genetic studies to precision medicine in alcohol dependence. Behav Pharmacol 27(2\u20133 Spec Issue):87\u201399","journal-title":"Behav Pharmacol"},{"key":"79_CR151","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/0006-3223(95)00432-7","volume":"40","author":"RM Swift","year":"1996","unstructured":"Swift RM, Davidson D, Whelihan W, Kuznetsov O (1996) Ondansetron alters human alcohol intoxication. Biol Psychiatry 40:514\u2013521","journal-title":"Biol Psychiatry"},{"key":"79_CR152","doi-asserted-by":"crossref","unstructured":"Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T (2013) Target inhibition networks: predicting selective combinations of druggable targets to bl9ck cancer survivial pathways. PLoS Comput Biol (9):e1003226","DOI":"10.1371\/journal.pcbi.1003226"},{"key":"79_CR153","doi-asserted-by":"publisher","unstructured":"Vatsalya V, Gowin JL, Schwandt ML, Momenan R, Coe MA, Hommer DW, Bartlett S, Heilig M, Ramchandani VA (2015) Effects of varenicline on neural correlates of alcohol salience in heavy drinkers. Int J Neuropsychopharmacol 18(12). pii: pyv068. doi: https:\/\/doi.org\/10.1093\/ijnp\/pyv068","DOI":"10.1093\/ijnp\/pyv068"},{"key":"79_CR154","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1523\/JNEUROSCI.0069-12.2012","volume":"32","author":"LF Vendruscolo","year":"2012","unstructured":"Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW, Logrip ML, Rivier C, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Heilig M, Koob GF (2012) Corticosteroid-dependent plasticity medicates compulsive alcohol drinking in rats. J Neurosci 32:7563\u20137571","journal-title":"J Neurosci"},{"key":"79_CR155","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI79828","volume":"125","author":"LF Vendruscolo","year":"2015","unstructured":"Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ (2015) J Clin Invest 125:3193\u20133197","journal-title":"J Clin Invest"},{"key":"79_CR156","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1530-0277.2008.00783.x","volume":"32","author":"K Voronin","year":"2008","unstructured":"Voronin K, Randall P, Myrick H, Anton R (2008) Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm\u2013possible influence of self-control. Alcohol Clin Exp Res 32:1954\u20131961","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-011-2199-2","volume":"216","author":"BJ Watson","year":"2011","unstructured":"Watson BJ, Wilson S, Griffin L, Kalk NJ, Taylor LG, Munafo MR, Lingford-Hughes AR, Nutt DJ (2011) A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology (Berl) 216:121\u2013129","journal-title":"Psychopharmacology (Berl)"},{"key":"79_CR158","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/acer.12257","volume":"38","author":"CJ Wong","year":"2014","unstructured":"Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ (2014) A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res 38:511\u2013520","journal-title":"Alcohol Clin Exp Res"},{"key":"79_CR159","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nbt1338","volume":"25","author":"MA Yildirim","year":"2007","unstructured":"Yildirim MA, Goh KL, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25:1119\u20131126","journal-title":"Nat Biotechnol"},{"key":"79_CR160","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1530-0277.2011.01532.x","volume":"35","author":"Y Zhou","year":"2011","unstructured":"Zhou Y, Colombo G, Carai MAM, Ho A, Gessa GL, Kreek MJ (2011) Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res 35:1876\u20131883","journal-title":"Alcohol Clin Exp Res"},{"issue":"Suppl)17","key":"79_CR161","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15288\/jsads.2014.s17.79","volume":"75","author":"LR Zindel","year":"2014","unstructured":"Zindel LR, Kranzler HR (2014) Pharmacotherapy of alcohol use disorders: Seventy-five years of progress. J Stud Alcohol Drugs 75(Suppl)17):79\u201388","journal-title":"J Stud Alcohol Drugs"}],"container-title":["Handbook of Experimental Pharmacology","The Neuropharmacology of Alcohol"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2017_79","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T06:36:57Z","timestamp":1719729417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2017_79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319965222","9783319965239"],"references-count":161,"URL":"https:\/\/doi.org\/10.1007\/164_2017_79","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"3 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}